Filter Results:
(619)
Show Results For
- All HBS Web
(619)
- People (4)
- News (113)
- Research (425)
- Events (3)
- Multimedia (4)
- Faculty Publications (260)
Show Results For
- All HBS Web
(619)
- People (4)
- News (113)
- Research (425)
- Events (3)
- Multimedia (4)
- Faculty Publications (260)
- 01 Oct 2011
- News
Resistance Is Futile
- Video
Dr. Silvia Gold
Dr. Silvia Gold, President of the Mundo Sano Foundation and co-founder of Grupo Insud, explains how patent expiration is important for innovation, recounting that her company has always won against large Western pharmaceutical companies that have sought legal action... View Details
- December 2007 (Revised May 2009)
- Case
Can PACIV (Puerto Rico) Serve European Customers?
Jorge Rodriguez-Gonzalez, PACIV's (Puerto Rico) founding CEO, is considering expanding PACIV's pharmaceutical manufacturing compliance services company to the U.K. and Europe. He has to decide whether to hire Wayne Snelgrove and how to define the scope of his... View Details
Keywords: Customer Focus and Relationships; Entrepreneurship; Cross-Cultural and Cross-Border Issues; Global Strategy; Pharmaceutical Industry; Pharmaceutical Industry; Europe; United Kingdom; Puerto Rico
Isenberg, Daniel J. "Can PACIV (Puerto Rico) Serve European Customers?" Harvard Business School Case 808-099, December 2007. (Revised May 2009.)
- September 2014 (Revised February 2015)
- Case
Pfizer and AstraZeneca: Marketing an Acquisition (A)
By: John A. Quelch and James Weber
In 2014, Pfizer proposed a friendly acquisition of AstraZeneca, but the AstraZeneca board resisted over price and strategy concerns. Was this good for pharmaceutical consumers? Pfizer, like pharmaceutical companies in general, faced difficulties in growing sales due to... View Details
Keywords: Health Care Policy; Mergers And Acquisitions; Marketing; Government Relations; Crisis Management; Decision Making; Growth and Development; Management; Markets; Strategy; Pharmaceutical Industry; United Kingdom; United States
Quelch, John A., and James Weber. "Pfizer and AstraZeneca: Marketing an Acquisition (A)." Harvard Business School Case 515-007, September 2014. (Revised February 2015.)
- 09 Nov 2011
- News
Resistance Is Futile
- 26 Apr 2010
- News
Pharma's Future Depends on These Three Trends
- August 2023 (Revised May 2024)
- Case
Dicerna Pharmaceuticals: Decision Making in Clinical Trial Design and Operations
By: Satish Tadikonda and Amanda McEwen
The success or failure of Dicerna Pharmaceuticals (Dicerna) as an emerging pharmaceutical company would likely hinge on its lead drug candidate Nedosiran and the company’s ability to see it successfully through clinical development. Ralf Rosskamp, Chief Medical... View Details
Keywords: Business Strategy; Health Testing and Trials; Product Development; Governing Rules, Regulations, and Reforms; Pharmaceutical Industry
Tadikonda, Satish, and Amanda McEwen. "Dicerna Pharmaceuticals: Decision Making in Clinical Trial Design and Operations." Harvard Business School Case 824-018, August 2023. (Revised May 2024.)
- October 2016 (Revised February 2017)
- Teaching Note
Alvogen
By: Daniel Isenberg, William R. Kerr and Alexis Brownell
Alvogen is an Icelandic pharmaceutical company that makes and sells generic drugs. Founder and CEO Robert Wessman is deciding whether to take on private equity investors willing to buy out all shareholders, merge with a large and publicly-traded US pharmaceutical... View Details
- January 2001
- Case
Abgenix and the XenoMouse
By: Robert J. Dolan
Abgenix has a unique method for generating antibodies useful in treating a number of diseases, including cancer. In early 2000, the company's cancer has performed very well in animal testing and is moving to early stage human testing. Abgenix must decide whether to... View Details
Keywords: Product Development; Marketing Strategy; Health Testing and Trials; Risk and Uncertainty; Technological Innovation; Innovation Strategy; Science-Based Business; Biotechnology Industry
Dolan, Robert J. "Abgenix and the XenoMouse." Harvard Business School Case 501-061, January 2001.
- 15 Feb 2011
- News
Who will blink in Genzyme, Sanofi price talks?
- September 1995
- Case
Ares-Serono
By: Michael Y. Yoshino, Jean-Pierre Jeannet and Carin-Isabel Knoop
Ares Serono, a medium-size Swiss pharmaceutical company, is the global leader in the field of fertility drugs. The company has successfully transformed into one of the very few biotech firms in Europe. The case treats a set of major strategic and organizational... View Details
Keywords: Geographic Location; Globalized Firms and Management; Asset Management; Balance and Stability; Expansion; Digital Platforms; Leadership Development; Health Care and Treatment; Transformation; Family Business; Problems and Challenges; Pharmaceutical Industry; Pharmaceutical Industry; Switzerland; Europe
Yoshino, Michael Y., Jean-Pierre Jeannet, and Carin-Isabel Knoop. "Ares-Serono." Harvard Business School Case 396-035, September 1995.
- 2022
- Book
Les multinationales suisses dans l'arène politique (1942–1993) [Swiss Multinationals in the Political Arena (1942–1993)]
By: Sabine Pitteloud
En décembre 2020, les Suisses votaient sur l’initiative populaire « pour des multinationales responsables ». Cet épisode récent a rappelé que la régulation de l’activité des sociétés multinationales fait l’objet de luttes politiques, auxquelles participent les... View Details
Keywords: Multinational Enterprise; Multinational Companies; Multinational Corporations; Lobbying; Business ＆ Government Relations; Labor Relations; Relocation; Offshoring And Outsourcing; Corporate Regulation; Transnational Regulation; Multinational Firms and Management; Business and Government Relations; Governing Rules, Regulations, and Reforms; International Relations; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry; Switzerland
Pitteloud, Sabine. Les multinationales suisses dans l'arène politique (1942–1993) [Swiss Multinationals in the Political Arena (1942–1993)]. Genève, Suisse: Librairie Droz, 2022, French ed.
- February 2009 (Revised December 2009)
- Case
Merck: Global Health and Access to Medicines
By: V. Kasturi Rangan and Katharine Lee
The case describes the effort of Merck, a global leader in pharmaceuticals, in making available its medicines to the poor. The challenge for the company (or for that matter, any pharmaceutical company) is how to integrate its business strategy with its corporate social... View Details
Keywords: Globalized Firms and Management; Health Care and Treatment; Emerging Markets; Corporate Social Responsibility and Impact; Poverty; Business Strategy; Pharmaceutical Industry
Rangan, V. Kasturi, and Katharine Lee. "Merck: Global Health and Access to Medicines." Harvard Business School Case 509-048, February 2009. (Revised December 2009.)
- July 2004 (Revised May 2005)
- Case
Pfizer's Virtual CIO (Abridged)
By: F. Warren McFarlan and Brian DeLacey
Discusses the IT organization and IT strategy issues facing Pfizer, one of the world's largest pharmaceutical companies. Managing over $1 billion of IT expense, the company has a committee approach for handling all critical IT decisions, an approach that is consistent... View Details
Keywords: Decision Making; Cost Management; Organizational Culture; Strategy; Information Technology; Pharmaceutical Industry
McFarlan, F. Warren, and Brian DeLacey. "Pfizer's Virtual CIO (Abridged)." Harvard Business School Case 305-018, July 2004. (Revised May 2005.)
- December 2000 (Revised January 2001)
- Background Note
Promise of Functional Foods, The
By: Ray A. Goldberg, Carin-Isabel Knoop and Laure Mougeot Stroock
This case presents a definition of functional foods or nutraceuticals (food or food ingredients that could provide a health benefit beyond the traditional nutrients they contain), a description of some of the major obstacles to their commercialization and... View Details
Keywords: Food; Private Sector; Public Sector; Health; Product Development; Production; Commercialization; Pharmaceutical Industry; Pharmaceutical Industry
Goldberg, Ray A., Carin-Isabel Knoop, and Laure Mougeot Stroock. "Promise of Functional Foods, The." Harvard Business School Background Note 901-013, December 2000. (Revised January 2001.)
- September 2023 (Revised April 2024)
- Case
Atomwise: Strategic Opportunities in AI for Pharma
By: Satish Tadikonda
Abraham Heifets and his co-founder, Izhar Wallach, had founded Atomwise to develop i) an AI engine to transform drug discovery by creating better medicines faster, and ii) a machine learning-based discovery engine that combined the power of convolutional neural... View Details
Keywords: Business Model; Business Startups; AI and Machine Learning; Science-Based Business; Technological Innovation; Pharmaceutical Industry; Pharmaceutical Industry
Tadikonda, Satish. "Atomwise: Strategic Opportunities in AI for Pharma." Harvard Business School Case 824-043, September 2023. (Revised April 2024.)
- October 2012
- Case
Sirtris Pharmaceuticals: Living Healthier, Longer (Abridged)
By: Toby Stuart and James Weber
Describes a set of key strategic decisions facing the scientific founder and CEO of a promising, early stage bio-pharmaceuticals company. Should the company establish a proposed alliance with a pharmaceutical firm? Should it create a nutraceuticals business in parallel... View Details
Keywords: Business Startups; Decision Choices and Conditions; Entrepreneurship; Growth and Development Strategy; Risk Management; Brands and Branding; Pharmaceutical Industry
Stuart, Toby, and James Weber. "Sirtris Pharmaceuticals: Living Healthier, Longer (Abridged)." Harvard Business School Case 813-029, October 2012.
- March 2008 (Revised June 2008)
- Case
Sirtris Pharmaceuticals: Living Healthier, Longer
Describes a set of key strategic decisions facing the scientific founder and CEO of a promising, early stage bio-pharmaceuticals company. Should the company establish a proposed alliance with a pharmaceutical firm? Should it create a nutraceuticals business in parallel... View Details
Keywords: Business Startups; Decision Choices and Conditions; Entrepreneurship; Growth and Development Strategy; Risk Management; Brands and Branding; Pharmaceutical Industry
Stuart, Toby, and David Kiron. "Sirtris Pharmaceuticals: Living Healthier, Longer." Harvard Business School Case 808-112, March 2008. (Revised June 2008.)
- March 2014 (Revised December 2014)
- Case
Vision 2020: Takeda and the Vaccine Business
By: John A. Quelch and Margaret L. Rodriguez
In 2014, Yasuchika Hasegawa was orchestrating the transformation of Takeda from a Japanese pharmaceutical company with a global footprint into a global company with a Japanese heritage. A 33-year veteran of Takeda, Hasegawa-san was appointed president of Takeda in 2003... View Details
Keywords: Health Care; Global; NGO; Public Health; Japan; GSK; Vaccine; Supply Chain; Market Entry; Health; Health Care and Treatment; Trade; Market Entry and Exit; Global Strategy; Pharmaceutical Industry; Pharmaceutical Industry
Quelch, John A., and Margaret L. Rodriguez. "Vision 2020: Takeda and the Vaccine Business." Harvard Business School Case 514-084, March 2014. (Revised December 2014.)